Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion Posted byZacks Equity Research January 11, 2022 Leave a comment on Horizon (HZNP) Submits sBLA for Krystexxa Label Expansion Horizon (HZNP) files a supplemental biologics license application to the FDA for Krystexxa plus methotrexate to treat people living with uncontrolled gout.